CASTLEFORD, England, December 9, 2011 /PRNewswire/ --
We are delighted to announce the first generic launch of Orlistat, generic equivalent to Xenical® (Orlistat) from Roche.
Orlistat from Teva UK Limited is available immediately as:
Product Strength Pack size Teva retail Price Orlistat 120mg capsule x 84 GBP27.60
Kim Innes, Commercial Director at Teva said: "We're delighted to be the first company to launch generic Orlistat in the UK.
"As the UK's leading supplier of generics, we're pleased not only to have the widest portfolio of our competitors, but also to show that we're well-placed when it comes to innovation and being the first to market."
Orlistat is a generic version of prescription-only Xenical® from Roche and is indicated in conjunction with a mildly hypocaloric diet for the treatments of obese patients with a body mass index (BMI) greater or equal to 30kg/m2, or overweight patients (BMI ≥ 28kg/m2) with associated risk factors.
New or existing customers can order through their local Teva Territory Sales Manager, by completing a online form found on http://www.tevauk.com, or by calling our dedicated Sales Liaison team on 0800-085-8621.
To find out more about Teva UK Limited, visit http://www.tevauk.com.
December 2011; CPE/11/045
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $16.1 billion in net sales in 2010.
For media enquiries, contact the Teva UK Limited Media team on +44(0)1977-628500, or email firstname.lastname@example.org.
SOURCE Teva UK Ltd